Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.
Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.
Read publication: JAMA Dermatology
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
0 Comments